AxoGen (AXGN) Akcija Цена
AxoGen Цена
Prihod je rastao 48,3 % godišnje u poslednjih 19 godina na 225,21 М USD. neto marža kompanije AxoGen sada iznosi -7,0 %, porasla sa -21,2 % pre nekoliko godina. AxoGen trenutno nudi dividendni prinos od oko 2,85 %. Medijana analitičke ciljane cene je 51,50 USD, odnosno iznad trenutnu cenu za 46,9 %. Od 16 analitičara 15 preporučuje kupovinu — ukupni konsenzus je Kupi.
Cena akcije AxoGen
Pristupite ovim podacima preko Eulerpool API-ja
100.000 zahteva/mes. besplatno · bez kartice
AxoGen poslovni model i analiza akcije
Često postavljana pitanja o akciji AxoGen
AxoGen Inc is a leading medical technology company focused on the development and commercialization of innovative solutions for peripheral nerve injuries. Their business model revolves around providing advanced surgical solutions to patients suffering from nerve damage. AxoGen offers a comprehensive portfolio of products and services that support nerve repair and regeneration, enabling patients to regain function and improve their quality of life. Through their cutting-edge technologies, AxoGen aims to revolutionize the field of peripheral nerve repair, bringing hope and relief to individuals with nerve injuries.
AxoGen Inc is primarily active in the healthcare industry.
The main competitors of AxoGen Inc in the market include Integra LifeSciences Holdings Corporation, Baxter International Inc., Stryker Corporation, and Medtronic plc.
AxoGen Inc. is a biotechnology company specializing in the development and commercialization of innovative surgical solutions for peripheral nerve injuries. Founded in 2002, AxoGen is headquartered in Alachua, Florida, and operates globally. The company is dedicated to advancing the science and understanding of nerve injury and regeneration through its proprietary Avance® Nerve Graft and AxoGuard® Nerve Protector products. With an experienced management team, AxoGen continues to drive innovation in nerve repair and restoration, providing hope and improved outcomes for patients suffering from nerve damage. AxoGen Inc. has established itself as a leader in the field, offering groundbreaking solutions to healthcare providers and patients worldwide.
AxoGen Inc has achieved several significant milestones throughout its history. The company has successfully developed and commercialized innovative nerve repair technology, making it a leader in the field. AxoGen has achieved FDA clearance and European CE mark approval for its products. It has also expanded its market presence by establishing distribution agreements with leading healthcare providers globally. AxoGen has consistently demonstrated strong financial performance, with increased revenues and record-breaking sales. The company's commitment to research and development has led to numerous patents and the introduction of groundbreaking surgical solutions. Overall, AxoGen Inc has made remarkable progress in transforming the field of nerve repair and continues to pave the way for future advancements.
AxoGen Inc is primarily present in the United States.
AxoGen Inc represents the values of innovation, collaboration, and patient-centricity. As a leading company in the field of nerve repair and regeneration, AxoGen is dedicated to developing and providing innovative solutions for patients with peripheral nerve injuries. Their corporate philosophy revolves around improving patient outcomes and enhancing the quality of life by delivering safe and effective treatments. By prioritizing collaboration with healthcare professionals and researchers, AxoGen ensures that their products are developed with the latest scientific advancements. With an unwavering commitment to patient well-being, AxoGen continues to make significant contributions to the field of nerve repair.
Analitičari trenutno postavljaju prosečnu ciljanu cenu 50,17 USD za akciju AxoGen (medijana: 51,50 USD), što znači +43,1 % u odnosu na poslednju cenu. Konsenzus se zasniva na 16 ocena.
16 analitičara trenutno ocenjuje akciju AxoGen: 15 preporučuje kupovinu, 1 držanje i 0 prodaju. Za 2026 analitičari očekuju da AxoGen ostvari prihod 282,57 М USD i zaradu po akciji 0,44 USD.
Po trenutnom kursu akcija AxoGen kotira 31,18 EUR (35,05 USD).
Akcija AxoGen (AXGN) kotira na 4 berze, uključujući: NASDAQ (AXGN), London (0HKD.L), Frankfurt (LT3.F).
AxoGen Inc is a medical device company specializing in the development, manufacturing, and marketing of nerve repair products. The company, founded in 2002 in Florida, USA, aims to help improve patients' quality of life and alleviate pain and impairments caused by damages to peripheral nerves. They offer a range of products tailored to the specific needs of patients with nerve injuries, including the AxoGuard® Nerve Protector, biologics, regenerative medicine, neurostimulation, and the AxoTouch Test. The AxoGuard® Nerve Protector is designed to prevent damage to peripheral nerves and consists of breathable, implantable sleeves that provide protection. It is typically used to protect or repair nerves after surgery or due to injuries. Biologics, another branch of AxoGen Inc, involves the use of biological materials to accelerate the healing process of injured nerves, such as stem cells, Botulinum toxin injection, and antibodies to promote repair. Regenerative medicine products utilize regenerative forces to accelerate healing and promote the formation of new tissue, with Avance® Nerve Graft being the flagship product made from frozen human nerves processed mechanically and enzymatically to obtain a highly pure and biocompatible product. Neurostimulation focuses on the use of electronic devices to stimulate the nervous system, helping to alleviate pain and expedite healing. AxoStim® electrostimulation systems are among the products in this field. The AxoTouch Test is a diagnostic tool used to diagnose nerve damage, measuring pressure and touch sensitivity in the patient's body. It consists of a handheld instrument, a touch sensitivity measurement device, and specialized software packages for data analysis. AxoGen Inc's business model revolves around providing products for nerve damage regeneration, offering a comprehensive range of products tailored to patients' specific needs. The company is dedicated to developing innovative technologies and products to enhance the lives of individuals suffering from nerve damage and associated pain and impairments.
očekivana prihod od AxoGen je 282,57 М USD. Ova cifra je zasnovana na trenutnim finansijskim podacima i odražava poslovne rezultate preduzeća.
očekivana dobit od AxoGen je 20,62 М USD. Neto dobit pokazuje profitabilnost preduzeća nakon odbitka svih troškova.
Odnos cene i zarade (KGV) za AxoGen je trenutno 79,79. KGV poredi sadašnju cenu akcije sa zaradom po akciji i pomaže investitorima da procene valuaciju akcije AxoGen.
Odnos cene i prihoda (KUV) za AxoGen je trenutno 5,82. KUV poredi tržišnu kapitalizaciju sa godišnjim prihodima i služi kao metrika valuacije za akciju AxoGen.
Eulpool score kvaliteta za AxoGen je 4/10.
ISIN za AxoGen je US05463X1063. ISIN (International Securities Identification Number) je globalno jedinstveni identifikator za hartije od vrednosti.
WKN za AxoGen je A1JMHK. WKN (Wertpapierkennnummer) je šestocifreni nemački broj za identifikaciju hartija od vrednosti.
Ticker za AxoGen je AXGN. Simbol tikera se koristi za trgovinu akcijama AxoGen na berzanskom tržištu.
AxoGen акција
AxoGen Peer grupa
AxoGen Тикер
AxoGen FIGI
Sve ključne metrke i detaljne analize AxoGen u dubinskoj analizi
Naša analiza akcija za akciju AxoGen uključuje važne finansijske pokazatelje kao što su prihod, profit, P/E odnos, P/S odnos, EBIT, kao i informacije o dividendama. Takođe, razmatramo aspekte poput akcija, tržišne kapitalizacije, dugova, kapitala i obaveza kompanije AxoGen. Ako tražite detaljnije informacije o ovim temama, na našim podstranicama vam nudimo opsežne analize: